BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

NEXT STORY
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
PREV STORY
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Novavax, Inc. of Class Action Lawsuit and Upcoming Deadline – NVAX

author_avatar
NASDAQ Market News

Mateon Announces Adjournment of Special Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), ...

author_avatar
NASDAQ Market News

New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19

author_avatar
NASDAQ Market News